GLP-1 receptor agonist medications — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and newer agents — were developed for type 2 diabetes and are now also approved for obesity and cardiovascular risk reduction. Four significant research findings published in June 2026 suggest these drugs may affect far more than the conditions they were designed to treat.
Together, the findings paint a picture of a drug class with broad systemic effects, some of which offer exciting potential benefits and others that require active clinical management. Here is what each found, and what it means if you or a family member is taking these medications.
